Cerebrospinal fluid from patients with multiple system atrophy promotes in vitro α-synuclein fibril formation

Neuroscience Letters

Volumn 491, Issue 1, 2011, Pages 48-52

  Hirohata, Mie ^a,b   Ono, Kenjiro ^a   Morinaga, Akiyoshi ^a   Ikeda, Tokuhei ^a   Yamada, Masahito ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b National Hospital Organization Iou National Hospital   (Japan)

Author keywords

Synuclein fibrils; Cerebrospinal fluid; Lewy body diseases; Multiple system atrophy; Parkinson's disease; Thioflavin S

Indexed keywords

ALPHA SYNUCLEIN; DIRECT YELLOW 7; THIOFLAVINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM; CEREBELLAR ATAXIA; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; ELECTRON MICROSCOPY; FEMALE; FIBER; FLUORESCENCE SPECTROSCOPY; HUMAN; IN VITRO STUDY; MALE; PARKINSON DISEASE; PH; PRIORITY JOURNAL; PROTEIN AGGREGATION; SHY DRAGER SYNDROME; TENSION HEADACHE;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; CEREBROSPINAL FLUID; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; NERVE DEGENERATION; NEUROFIBRILS; SPINOCEREBELLAR ATAXIAS; TENSION-TYPE HEADACHE;

EID: 79951513184     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.01.005     Document Type: Article

References (39)

1. Abdo W.F., De Jong D., Hendriks J.C., Horstink M.W., Kremer B.P., Bloem B.R., Verbeek M.M. Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease. Mov. Disord. 2003, 19:571-579.
2. Borghi R., Marchese R., Negro A., Marinelli L., Forloni G., Zaccheo D., Abbruzzese G., Tabaton M. Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci. Lett. 2000, 287:65-67.
3. Braak H., Del Tredici K., Rüb U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
4. Caughey B., Lansbury P.T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 2003, 26:267-298.
5. El-Agnaf O.M., Salem S.A., Paleologou K.E., Cooper L.J., Fullwood N.J., Gibson M.J., Curran M.D., Court J.A., Mann D.M., Ikeda S., Cookson M.R., Hardy J., Allsop D. α-Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 2003, 17:1945-1947.
6. Gai W.P., Yuan H.X., Li X.Q., Power J.T., Blumbergs P.C., Jensen P.H. In situ and in vitro study of colocalization and segregation of α-synuclein, ubiquitin, and lipids in Lewy bodies. Exp. Neurol. 2000, 166:324-333.
7. Gai W.P., Pountney D.L., Power J.H., Li Q.X., Culvenor J.G., McLean C.A., Jensen P.H., Blumbergs P.C. α-Synuclein fibrils constitute the central core of oligodendroglial inclusion filaments in multiple system atrophy. Exp. Neurol. 2003, 181:68-78.
8. Gilman S., Low P.A., Quinn N., Albanese A., Ben-Shlomo Y., Fowler C.J., Kaufmann H., Klockgether T., Lang A.E., Lantos P.L., Litvan I., Mathias C.J., Oliver E., Robertson D., Schatz I., Wenning G.K. Consensus statement on the diagnosis of multiple system atrophy. J. Neurol. Sci. 1999, 163:94-98.
9. Gilman S., Wenning G.K., Low P.A., Brooks D.J., Mathias C.J., Trojanowski J.Q., Wood N.W., Colosimo C., Dürr A., Fowler C.J., Kaufmann H., Klockgether T., Lees A., Poewe W., Quinn N., Revesz T., Robertson D., Sandroni P., Seppi K., Vidailhet M. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008, 71:670-676.
10. Goldberg M.S., Lansbury P.T. Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson's disease?. Nat. Cell Biol. 2000, 2:E115-119.
11. Holmberg B., Rosengren L., Karlsson J.E., Johnels B. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease. Mov. Disord. 1998, 13:70-77.
12. Holmberg B., Johnels B., Blennow K., Rosengren L. Cerebrospinal fluid Aβ42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov. Disord. 2003, 18:186-190.
13. Hughes A.J., Ben-Shlomo Y., Daniel S.E., Lees A.J. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992, 42:1142-1146.
14. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H.A., Kittel A., Saitoh T. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995, 14:467-475.
15. Jakes R., Spillantini M.G., Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 1994, 345:27-32.
16. Kleine T.O., Merten B. Rapid manual immunoturbidimetric and immunonephelometric assays of prealbumin, albumin, IgG, IgA and IgM in cerebrospinal fluid. J. Clin. Chem. Clin. Biochem. 1980, 18:245-254.
17. Lee H.J., Patel S., Lee S.J. Intravesicular localization and exocytosis of α-synuclein and its aggregates. J. Neurosci. 2005, 25:6016-6024.
18. Lindersson E., Lundvig D., Petersen C., Madsen P., Nyengaard J.R., Højrup P., Moos T., Otzen D., Gai W.P., Blumbergs P.C., Jensen P.H. p25α stimulates α-synuclein aggregation and is co-localized with aggregated α-synuclein in α-synucleinopathies. J. Biol. Chem. 2005, 280:5703-5715.
19. Liu I.H., Uversky V.N., Munishkina L.A., Fink A.L., Halfter W., Cole G.J. Agrin binds α-synuclein and modulates α-synuclein fibrillation. Glycobiology 2005, 15:1320-1331.
20. Liu J., Zhang J.P., Shi M., Quinn T., Bradner J., Beyer R., Chen S., Zhang J., Rab11a HSP90 regulate recycling of extracellular α-synuclein. J. Neurosci. 2009, 29:1480-1485.
21. Lücking C.B., Brice A., Alpha-synuclein Parkinson's disease. Cell. Mol. Life Sci. 2000, 57:1894-1908.
22. Marshall T., Williams K.M. Protein determination in cerebrospinal fluid by protein dye-binding assay. Br. J. Biomed. Sci. 2000, 57:281-286.
23. McKeith I.G., Galasko D., Kosaka K., Perry E.K., Dickson D.W., Hansen L.A., Salmon D.P., Lowe J., Mirra S.S., Byrne E.J., Lennox G., Quinn N.P., Edwardson J.A., Ince P.G., Bergeron C., Burns A., Miller B.L., Lovestone S., Collerton D., Jansen E.N., Ballard C., de Vos R.A., Wilcock G.K., Jellinger K.A., Perry R.H. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996, 47:1113-1124.
24. Mollenhauer B., Cullen V., Kahn I., Krastins B., Outeiro T.F., Pepivani I., Ng J., Schulz-Schaeffer W., Kretzschmar H.A., McLean P.J., Trenkwalder C., Sarracino D.A., Vonsattel J.P., Locascio J.J., El-Agnaf O.M., Schlossmacher M.G. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 2008, 213:315-325.
25. Noguchi-Shinohara M., Tokuda T., Yoshita M., Kasai T., Ono K., Nakagawa M., El-Agnaf O.M., Yamada M.C.S.F. α-Synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res. 2009, 1251:1-6.
26. Ono K., Noguchi-Shinohara M., Yoshita M., Naiki H., Yamada M. Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances α-synuclein fibril formation in vitro. Exp. Neurol. 2007, 203:579-583.
27. Ono K., Hirohata M., Yamada M. α-Synuclein assembly as a therapeutic target of Parkinson's disease and related disorders. Curr. Pharm. Des. 2008, 14:3247-3266.
28. Ono K., Condron M.M., Teplow D.B. Effects of the english (H6R) and tottori (D7N) familial Alzheimer disease mutations on amyloid β-protein assembly and toxicity. J. Biol. Chem. 2010, 285:23186-23197.
29. Paleologou K.E., Kragh C.L., Mann D.M., Salem S.A., Al-Shami R., Allsop D., Hassan A.H., Jensen P.H., El-Agnaf O.M. Detection of elevated levels of soluble α-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 2009, 132:1093-1101.
30. Paravastu A.K., Leapman R.D., Yau W.M., Tycko R. Molecular structural basis for polymorphism in Alzheimer's β-amyloid fibrils. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:18349-18354.
31. Parnetti L., Balducci C., Pierguidi L., De Carlo C., Peducci M., D'Amore C., Padiglioni C., Mastrocola S., Persichetti E., Paciotti S., Bellomo G., Tambasco N., Rossi A., Beccari T., Calabresi P. Cerebrospinal fluid β-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies. Neurobiol. Dis. 2009, 34:484-486.
32. Petkova A.T., Yau W.M., Tycko R. Experimental constraints on quaternary structure in Alzheimer's β-amyloid fibrils. Biochemistry 2006, 45:498-512.
33. Sangchot P., Sharma S., Chetsawang B., Porter J., Govitrapong P., Ebadi M. Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and α-synuclein translocation in SK-N-SH cells in culture. Dev. Neurosci. 2002, 24:143-153.
34. Tokuda T., Salem S.A., Allsop D., Mizuno T., Nakagawa M., Qureshi M.M., Locascio J.J., Schlossmacher M.G., El-Agnaf O.M. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 2006, 349:162-166.
35. Uversky V.N., Li J., Fink A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human α-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 2001, 276:44284-44296.
36. Wenning G.K., Ben Shlomo Y., Magalhães M., Daniel S.E., Quinn N.P. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994, 117:835-845.
37. Wood S.J., Wypych J., Steavenson S., Louis J-C., Citron M., Biere A.L. α-Synuclein fibrillogenesis is nucleation dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 1999, 274:19509-19512.
38. Yonetani M., Nonaka T., Masuda M., Inukai Y., Oikawa T., Hisanaga S., Hasegawa M. Conversion of wild-type α-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. J. Biol. Chem. 2009, 284:7940-7950.
39. Zhang W., Wang T., Pei Z., Miller D.S., Wu X., Block M.L., Wilson B., Zhang W., Zhou Y., Hong J.S., Zhang J. Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005, 19:533-542.